| Schedule of net revenues by product |
The following tables detail AbbVie's worldwide net revenues: | | | | | | | | | | | | | | | | | | | | | | years ended December 31 (in millions) | 2025 | | 2024 | | 2023 | | Immunology | | | | | | | Skyrizi | United States | $ | 15,202 | | | $ | 10,086 | | | $ | 6,753 | | | International | 2,360 | | | 1,632 | | | 1,010 | | | Total | $ | 17,562 | | | $ | 11,718 | | | $ | 7,763 | | | Rinvoq | United States | $ | 5,940 | | | $ | 4,259 | | | $ | 2,824 | | | International | 2,364 | | | 1,712 | | | 1,145 | | | Total | $ | 8,304 | | | $ | 5,971 | | | $ | 3,969 | | | Humira | United States | $ | 3,062 | | | $ | 7,142 | | | $ | 12,160 | | | International | 1,478 | | | 1,851 | | | 2,244 | | | Total | $ | 4,540 | | | $ | 8,993 | | | $ | 14,404 | | | Neuroscience | | | | | | Vraylar | United States | $ | 3,612 | | | $ | 3,260 | | | $ | 2,755 | | | International | 9 | | | 7 | | | 4 | | | Total | $ | 3,621 | | | $ | 3,267 | | | $ | 2,759 | | Botox Therapeutic | United States | $ | 3,151 | | | $ | 2,718 | | | $ | 2,476 | | | International | 618 | | | 565 | | | 515 | | | Total | $ | 3,769 | | | $ | 3,283 | | | $ | 2,991 | | Ubrelvy | United States | $ | 1,239 | | | $ | 981 | | | $ | 803 | | | International | 32 | | | 25 | | | 12 | | | Total | $ | 1,271 | | | $ | 1,006 | | | $ | 815 | | Qulipta | United States | $ | 906 | | | $ | 628 | | | $ | 405 | | | International | 130 | | | 30 | | | 3 | | | Total | $ | 1,036 | | | $ | 658 | | | $ | 408 | | Vyalev | United States | $ | 167 | | | $ | 1 | | | $ | — | | | International | 315 | | | 98 | | | 3 | | | Total | $ | 482 | | | $ | 99 | | | $ | 3 | | | Duodopa | United States | $ | 73 | | | $ | 96 | | | $ | 97 | | | International | 308 | | | 351 | | | 371 | | | Total | $ | 381 | | | $ | 447 | | | $ | 468 | |
| | | | | | | | | | | | | | | | | | | | | | years ended December 31 (in millions) | 2025 | | 2024 | | 2023 | Other Neuroscience | United States | $ | 192 | | | $ | 223 | | | $ | 254 | | | International | 15 | | | 16 | | | 19 | | | Total | $ | 207 | | | $ | 239 | | | $ | 273 | | | Oncology | | | | | | | Imbruvica | United States | $ | 2,048 | | | $ | 2,448 | | | $ | 2,665 | | | Collaboration revenues | 821 | | | 899 | | | 931 | | | Total | $ | 2,869 | | | $ | 3,347 | | | $ | 3,596 | | | Venclexta | United States | $ | 1,306 | | | $ | 1,234 | | | $ | 1,087 | | | International | 1,486 | | | 1,349 | | | 1,201 | | | Total | $ | 2,792 | | | $ | 2,583 | | | $ | 2,288 | | | Elahere | United States | $ | 607 | | | $ | 477 | | | $ | — | | | International | 83 | | | 2 | | | — | | | Total | $ | 690 | | | $ | 479 | | | $ | — | | | Epkinly | Collaboration revenues | $ | 181 | | | $ | 118 | | | $ | 28 | | | International | 90 | | | 28 | | | 3 | | | Total | $ | 271 | | | $ | 146 | | | $ | 31 | | | Other Oncology | United States | $ | 33 | | | $ | — | | | $ | — | | | Aesthetics | | | | | | Botox Cosmetic | United States | $ | 1,504 | | | $ | 1,682 | | | $ | 1,670 | | | International | 1,098 | | | 1,038 | | | 1,012 | | | Total | $ | 2,602 | | | $ | 2,720 | | | $ | 2,682 | | Juvederm Collection | United States | $ | 385 | | | $ | 469 | | | $ | 519 | | | International | 608 | | | 708 | | | 859 | | | Total | $ | 993 | | | $ | 1,177 | | | $ | 1,378 | | Other Aesthetics | United States | $ | 1,101 | | | $ | 1,118 | | | $ | 1,060 | | | International | 164 | | | 161 | | | 174 | | | Total | $ | 1,265 | | | $ | 1,279 | | | $ | 1,234 | | | Eye Care | | | | | | | Ozurdex | United States | $ | 124 | | | $ | 138 | | | $ | 143 | | | International | 369 | | | 356 | | | 329 | | | Total | $ | 493 | | | $ | 494 | | | $ | 472 | | Lumigan/Ganfort | United States | $ | 189 | | | $ | 187 | | | $ | 173 | | | International | 221 | | | 242 | | | 259 | | | Total | $ | 410 | | | $ | 429 | | | $ | 432 | | Alphagan/Combigan | United States | $ | 53 | | | $ | 95 | | | $ | 121 | | | International | 144 | | | 153 | | | 151 | | | Total | $ | 197 | | | $ | 248 | | | $ | 272 | | Other Eye Care | United States | $ | 588 | | | $ | 644 | | | $ | 815 | | | International | 421 | | | 427 | | | 424 | | | Total | $ | 1,009 | | | $ | 1,071 | | | $ | 1,239 | | | Other Key Products | | | | | | | | Mavyret | United States | $ | 635 | | | $ | 595 | | | $ | 659 | | | International | 682 | | | 716 | | | 771 | | | Total | $ | 1,317 | | | $ | 1,311 | | | $ | 1,430 | | | Creon | United States | $ | 1,512 | | | $ | 1,383 | | | $ | 1,268 | | Linzess/Constella | United States | $ | 864 | | | $ | 916 | | | $ | 1,073 | | | International | 43 | | | 38 | | | 35 | | | Total | $ | 907 | | | $ | 954 | | | $ | 1,108 | | | All other | | $ | 2,627 | | | $ | 3,032 | | | $ | 3,035 | | | Total net revenues | | $ | 61,160 | | | $ | 56,334 | | | $ | 54,318 | |
|
| Schedule of net revenues to external customers by geographic area |
Net revenues to external customers by geographic area, based on product shipm ent destination, were as follows: | | | | | | | | | | | | | | | | | | | years ended December 31 (in millions) | 2025 | | 2024 | | 2023 | | United States | $ | 46,603 | | | $ | 43,029 | | | $ | 41,883 | | | Germany | 1,738 | | | 1,465 | | | 1,266 | | | Japan | 1,274 | | | 1,122 | | | 1,008 | | | Canada | 1,222 | | | 1,088 | | | 1,076 | | | China | 1,006 | | | 917 | | | 950 | | | France | 806 | | | 776 | | | 780 | | | United Kingdom | 626 | | | 522 | | | 417 | | | Spain | 609 | | | 528 | | | 501 | | | Italy | 580 | | | 511 | | | 484 | | | Brazil | 478 | | | 464 | | | 439 | | | Australia | 459 | | | 463 | | | 472 | | | All other countries | 5,759 | | | 5,449 | | | 5,042 | | | Total net revenues | $ | 61,160 | | | $ | 56,334 | | | $ | 54,318 | |
|